BAP1 Haploinsufficiency Predicts a Distinct Immunogenic Class of Malignant Peritoneal Mesothelioma

Raunak Shrestha, N Nabavi, Y Lin, F Mo, S Anderson, S Volik, H H Adomat, D Lin, H Xue, X Dong, R Shukin, RH Bell, B McConeghy, A Haegert, S Brahmbhatt, E Li, HZ Oo, A Hurtado-Coll, L Fazli, J Zhou, Y McConnell, A McCart, A Lowy, GB Morin, T Chen, M Daugaard, SC Sahinalp, F Hach, S Le Bihan, ME Gleave, Y Wang, A Churg, CC Collins

Feb 7, 2019

Our paper describing a potentially new treatment for Peritoneal #Mesothelioma published today in @GenomeMedicine https://t.co/admejVvX5K @VanProstateCtr #PrecisionOncology #Immunotherapy #Cancer #Genomics (1/n) pic.twitter.com/mWrsjpTsr1
— Raunak Shrestha (@raunakms) February 18, 2019

Great to see our work ( https://t.co/admejVvX5K ) making a mark in the field. Thanks @MLadanyi @fsanchezvega @MGZauderer for highlighting our work. https://t.co/s1cTVs2TgD #Mesothelioma #PeritonealMesothelioma #Immunotherapy
— Raunak Shrestha (@raunakms) March 27, 2019

BAP1 Haploinsufficiency Predicts a Distinct Immunogenic Class of Malignant Peritoneal Mesothelioma

Raunak Shrestha

Assistant Professor